Abe N, Watanabe T, Sugiyama M, Uchimura H, Chiappetta G, Fusco A, and Atomi Y (1999). Determination of high mobility group I(Y) expression level in colorectal neoplasias: a potential diagnostic marker. Cancer Res 59:1169-1174.
Abe N, Watanabe T, Masaki T, Mori T, Sugiyama M, Uchimura H, Fujioka Y, Chiappetta G, Fusco A, and Atomi Y (2000). Pancreatic duct cell carcinomas express high levels of high mobility group I(Y) proteins. Cancer Res 60:3117-3122.
Abe N, Watanabe T, Suzuki Y, Matsumoto N, Masaki T, Mori T, Sugiyama M, Chiappetta G, Fusco A, and Atomi Y (2003). An increased high-mobility group A2 expression level is associated with malignant phenotype in pancreatic exocrine tissue. Br J Cancer 89:2104-2109.
Abraham E, Arcaroli J, Carmody A, Wang H, and Tracey KJ (2000). HMG-1 as a mediator of acute lung inflammation. J Immunol 165:2950-2954.
Anan K, Morisaki T, Katano M, Ikubo A, Kitsuki H, Uchiyama A, Kuroki S, Tanaka M, and Torisu M (1996). Vascular endothelial growth factor and platelet-derived growth factor are potential angiogenic and metastatic factors in human breast cancer.
Surgery 119:333-339.
Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, Erlandsson-Harris H, Janson A, Kokkola R, Zhang M, Yang H, and Tracey KJ (2000). High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 192:565-570.
Arlotta P, Tai AK, Manfioletti G, Clifford C, Jay G, and Ono SJ (2000). Transgenic mice expressing a truncated form of the high mobility group I-C protein develop adiposity and an abnormally high prevalence of lipomas. J Biol Chem 275:14394-14400.
Ashar HR, Fejzo MS, Tkachenko A, Zhou X, Fletcher JA, Weremowicz S, Morton CC, and Chada K (1995). Disruption of the architectural factor HMGI-C: DNA-binding AT hook motifs fused in lipomas to distinct transcriptional regulatory domains. Cell 82:57-65.
Baldassarre G, Battista S, Belletti B, Thakur S, Pentimalli F, Trapasso F, Fedele M, Pierantoni G, Croce CM, and Fusco A (2003). Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma. Mol Cell Biol 23:2225-2238.
Bamberger AM, Sudahl S, Bamberger CM, Schulte HM, and Loning T (1999).
Expression patterns of the cell-cycle inhibitor p27 and the cell-cycle promoter cyclin E in the human placenta throughout gestation: implications for the control of proliferation. Placenta 20:401-406.
Bamberger AM, Makrigiannakis A, Roser K, Radde J, Carstens T, Flohr AM, Bamberger CM, Bullerdiek J, and Loning T (2003). Expression of the high-mobility group protein HMGI(Y) in human trophoblast: potential role in trophoblast invasion of maternal tissue. Virchows Arch 443:649-654.
Bandiera A, Bonifacio D, Manfioletti G, Mantovani F, Rustighi A, Zanconati F, Fusco A, Di Bonito L, and Giancotti V (1998). Expression of HMGI(Y) proteins in squamous intraepithelial and invasive lesions of the uterine cervix. Cancer Res 58:426-431.
Battista S, Fidanza V, Fedele M, Klein-Szanto AJ, Outwater E, Brunner H, Santoro M, Croce CM, and Fusco A (1999). The expression of a truncated HMGI-C gene induces gigantism associated with lipomatosis. Cancer Res 59:4793-4797.
Battista S, Pentimalli F, Baldassarre G, Fedele M, Fidanza V, Croce CM, and Fusco A (2003). Loss of Hmga1 gene function affects embryonic stem cell lympho-hematopoietic differentiation. FASEB J 17:1496-1498.
Berlingieri MT, Pierantoni GM, Giancotti V, Santoro M, and Fusco A (2002). Thyroid cell transformation requires the expression of the HMGA1 proteins. Oncogene 21:2971-2980.
Berner JM, Meza-Zepeda LA, Kools PF, Forus A, Schoenmakers EF, Van de Ven WJ, Fodstad O, and Myklebost O (1997). HMGIC, the gene for an architectural transcription factor, is amplified and rearranged in a subset of human sarcomas.
Oncogene 14:2935-2941.
Blank C, Rogalla P, Tran KH, and Bullerdiek J (2000). A novel high mobility group protein gene is a candidate for Xp22 abnormalities in uterine leiomyomas and other benign tumors. Cancer Genet Cytogenet 121:172-180.
Boer PH, Adra CN, Lau YF, and McBurney MW (1987). The testis-specific phosphoglycerate kinase gene pgk-2 is a recruited retroposon. Mol Cell Biol 7:3107-3112.
Boonyaratanakornkit V, Melvin V, Prendergast P, Altmann M, Ronfani L, Bianchi ME, Taraseviciene L, Nordeen SK, Allegretto EA, and Edwards DP (1998). High-mobility group chromatin proteins 1 and 2 functionally interact with steroid hormone receptors to enhance their DNA binding in vitro and transcriptional activity in mammalian cells.
Mol Cell Biol 18:4471-4487.
Borrmann L, Kim I, Schultheiss D, Rogalla P, and Bullerdiek J (2001). Regulation of the expression of HMG1, a co-activator of the estrogen receptor. Anticancer Res 21:301-305.
Bostrom H, Willetts K, Pekny M, Leveen P, Lindahl P, Hedstrand H, Pekna M, Hellstrom M, Gebre-Medhin S, Schalling M, Nilsson M, Kurland S, Tornell J, Heath JK, and Betsholtz C (1996). PDGF-A signaling is a critical event in lung alveolar myofibroblast development and alveogenesis. Cell 85:863-873.
Brezniceanu ML, Volp K, Bosser S, Solbach C, Lichter P, Joos S, and Zornig M (2003). HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J 17:1295-1297.
Bussemakers MJ, Van de Ven WJ, Debruyne FM, and Schalken JA (1991).
Identification of high mobility group protein I(Y) as potential progression marker for prostate cancer by differential hybridization analysis. Cancer Res 51:606-611.
Bustin M (2001). Revised nomenclature for high mobility group (HMG) chromosomal proteins. Trends Biochem Sci 26:152-153.
Cabart P, Kalousek I, Jandova D, and Hrkal Z (1995). Differential expression of nuclear HMG1, HMG2 proteins and H1(zero) histone in various blood cells. Cell Biochem Funct 13:125-133.
Calogero S, Grassi F, Aguzzi A, Voigtlander T, Ferrier P, Ferrari S, and Bianchi ME (1999). The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nat Genet 22:276-280.
Chau KY, Patel UA, Lee KL, Lam HY, and Crane-Robinson C (1995). The gene for the human architectural transcription factor HMGI-C consists of five exons each coding for a distinct functional element. Nucleic Acids Res 23:4262-4266.
Chau KY, Lam HY, and Lee KL (1998). Estrogen treatment induces elevated expression of HMG1 in MCF-7 cells. Exp Cell Res 241:269-272.
Chiappetta G, Bandiera A, Berlingieri MT, Visconti R, Manfioletti G, Battista S, Martinez-Tello FJ, Santoro M, Giancotti V, and Fusco A (1995). The expression of the high mobility group HMGI (Y) proteins correlates with the malignant phenotype of human thyroid neoplasias. Oncogene 10:1307-1314.
Chiappetta G, Avantaggiato V, Visconti R, Fedele M, Battista S, Trapasso F, Merciai BM, Fidanza V, Giancotti V, Santoro M, Simeone A, and Fusco A (1996). High level expression of the HMGI (Y) gene during embryonic development. Oncogene 13:2439-2446.
Chiappetta G, Tallini G, De Biasio MC, Manfioletti G, Martinez-Tello FJ, Pentimalli F, de Nigris F, Mastro A, Botti G, Fedele M, Berger N, Santoro M, Giancotti V, and Fusco A (1998). Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma. Cancer Res 58:4193-4198.
Chiappetta G, Manfioletti G, Pentimalli F, Abe N, Di Bonito M, Vento MT, Giuliano A, Fedele M, Viglietto G, Santoro M, Watanabe T, Giancotti V, and Fusco A (2001).
High mobility group HMGI(Y) protein expression in human colorectal hyperplastic and neoplastic diseases. Int J Cancer 91:147-151.
Choi YR, Kim H, Kang HJ, Kim NG, Kim JJ, Park KS, Paik YK, Kim HO, and Kim H (2003). Overexpression of high mobility group box 1 in gastrointestinal stromal tumors with KIT mutation. Cancer Res 63:2188-2193.
Dal Cin P, Wanschura S, Christiaens MR, Van dB, I, Moerman P, Polito P, Kazmierczak B, Bullerdiek J, and Van Den BH (1997). Hamartoma of the breast with involvement of 6p21 and rearrangement of HMGIY. Genes Chromosomes Cancer 20:90-92.
Degryse B, Bonaldi T, Scaffidi P, Muller S, Resnati M, Sanvito F, Arrigoni G, and Bianchi ME (2001). The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J Cell Biol 152:1197-1206.
Dolde CE, Mukherjee M, Cho C, and Resar LM (2002). HMG-I/Y in human breast cancer cell lines. Breast Cancer Res Treat 71:181-191.
Droemann D, Goldmann T, Branscheid D, Clark R, Dalhoff K, Zabel P, and Vollmer E (2003). Toll-like receptor 2 is expressed by alveolar epithelial cells type II and macrophages in the human lung. Histochem Cell Biol 119:103-108.
Enzinger FM (1988). Soft tissue tumors. Mosby, St. Louis, Washington, Toronto.
Falvo JV, Thanos D, and Maniatis T (1995). Reversal of intrinsic DNA bends in the IFN beta gene enhancer by transcription factors and the architectural protein HMG I(Y). Cell 83:1101-1111.
Fedele M, Bandiera A, Chiappetta G, Battista S, Viglietto G, Manfioletti G, Casamassimi A, Santoro M, Giancotti V, and Fusco A (1996). Human colorectal carcinomas express high levels of high mobility group HMGI(Y) proteins. Cancer Res 56:1896-1901.
Fedele M, Berlingieri MT, Scala S, Chiariotti L, Viglietto G, Rippel V, Bullerdiek J, Santoro M, and Fusco A (1998). Truncated and chimeric HMGI-C genes induce neoplastic transformation of NIH3T3 murine fibroblasts. Oncogene 17:413-418.
Ferrari S, Finelli P, Rocchi M, and Bianchi ME (1996). The active gene that encodes human high mobility group 1 protein (HMG1) contains introns and maps to chromosome 13. Genomics 35:367-371.
Flohr AM, Rogalla P, Meiboom M, Borrmann L, Krohn M, Thode-Halle B, and Bullerdiek J (2001). Variation of HMGB1 expression in breast cancer. Anticancer Res 21:3881-3885.
Flohr AM, Rogalla P, Bonk U, Puettmann B, Buerger H, Gohla G, Packeisen J, Wosniok W, Loeschke S, and Bullerdiek J (2003a). High mobility group protein HMGA1 expression in breast cancer reveals a positive correlation with tumour grade.
Histol Histopathol 18:999-1004.
Flohr AM, Hackenbeck T, Schlueter C, Rogalla P, and Bullerdiek J (2003b). DNase I treatment of cDNA first strands prevents RT-PCR amplification of contaminating DNA sequences. Biotechniques 35:920-2, 924, 926.
Friedmann M, Holth LT, Zoghbi HY, and Reeves R (1993). Organization, inducible-expression and chromosome localization of the human HMG-I(Y) nonhistone protein gene. Nucleic Acids Res 21:4259-4267.
Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, Bennett LM, Haugen-Strano A, Swensen J, Miki Y, and . (1994). BRCA1 mutations in primary breast and ovarian carcinomas. Science 266:120-122.
Gattas GJ, Quade BJ, Nowak RA, and Morton CC (1999). HMGIC expression in human adult and fetal tissues and in uterine leiomyomata. Genes Chromosomes Cancer 25:316-322.
Ge H and Roeder RG (1994). The high mobility group protein HMG1 can reversibly inhibit class II gene transcription by interaction with the TATA-binding protein. J Biol Chem 269:17136-17140.
Goldmann T, Wiedorn KH, Kuhl H, Olert J, Branscheid D, Pechkovsky D, Zissel G, Galle J, Muller-Quernheim J, and Vollmer E (2002). Assessment of transcriptional gene activity in situ by application of HOPE-fixed, paraffin-embedded tissues. Pathol Res Pract 198:91-95.
Goldmann T, Flohr AM, Murua Escobar H, Gerstmayer B, Janssen U, Bosio A, Loeschke S, Vollmer E, and Bullerdiek J (accepted). The HOPE-technique permits Northern blot and microarray analyses in paraffin-embedded tissues. Pathol Res Pract.
Goodwin GH and Johns EW (1973). Isolation and characterisation of two calf-thymus chromatin non-histone proteins with high contents of acidic and basic amino acids.
Eur J Biochem 40:215-219.
Grosschedl R, Giese K, and Pagel J (1994). HMG domain proteins: architectural elements in the assembly of nucleoprotein structures. Trends Genet 10:94-100.
Guazzi S, Strangio A, Franzi AT, and Bianchi ME (2003). HMGB1, an architectural chromatin protein and extracellular signalling factor, has a spatially and temporally restricted expression pattern in mouse brain. Gene Expr Patterns 3:29-33.
Guldner HH, Szostecki C, Schroder P, Matschl U, Jensen K, Luders C, Will H, and Sternsdorf T (1999). Splice variants of the nuclear dot-associated Sp100 protein contain homologies to HMG-1 and a human nuclear phosphoprotein-box motif. J Cell Sci 112 ( Pt 5):733-747.
Hanauer A and Mandel JL (1984). The glyceraldehyde 3 phosphate dehydrogenase gene family: structure of a human cDNA and of an X chromosome linked pseudogene; amazing complexity of the gene family in mouse. EMBO J 3:2627-2633.
Hauke S, Flohr AM, Rogalla P, and Bullerdiek J (2002). Sequencing of intron 3 of HMGA2 uncovers the existence of a novel exon. Genes Chromosomes Cancer 34:17-23.
He Q, Liang CH, and Lippard SJ (2000). Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin. Proc Natl Acad Sci U S A 97:5768-5772.
Heldin CH (1997). Simultaneous induction of stimulatory and inhibitory signals by PDGF. FEBS Lett 410:17-21.
Hennig Y, Rogalla P, Wanschura S, Frey G, Deichert U, Bartnitzke S, and Bullerdiek J (1997). HMGIC expressed in a uterine leiomyoma with a deletion of the long arm of chromosome 7 along with a 12q14-15 rearrangement but not in tumors showing del(7) as the sole cytogenetic abnormality. Cancer Genet Cytogenet 96:129-133.
Hirning-Folz U, Wilda M, Rippe V, Bullerdiek J, and Hameister H (1998). The expression pattern of the Hmgic gene during development. Genes Chromosomes Cancer 23:350-357.
Holth LT, Thorlacius AE, and Reeves R (1997). Effects of epidermal growth factor and estrogen on the regulation of the HMG-I/Y gene in human mammary epithelial cell lines. DNA Cell Biol 16:1299-1309.
Hori O, Brett J, Slattery T, Cao R, Zhang J, Chen JX, Nagashima M, Lundh ER, Vijay S, Nitecki D, and . (1995). The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co- expression of rage and amphoterin in the developing nervous system. J Biol Chem 270:25752-25761.
Huttunen HJ, Fages C, Kuja-Panula J, Ridley AJ, and Rauvala H (2002). Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer Res 62:4805-4811.
Jantzen HM, Admon A, Bell SP, and Tjian R (1990). Nucleolar transcription factor hUBF contains a DNA-binding motif with homology to HMG proteins. Nature 344:830-836.
Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, and Thun MJ (2003). Cancer statistics, 2003. CA Cancer J Clin 53:5-26.
Kawahara N, Tanaka T, Yokomizo A, Nanri H, Ono M, Wada M, Kohno K, Takenaka K, Sugimachi K, and Kuwano M (1996). Enhanced coexpression of thioredoxin and high mobility group protein 1 genes in human hepatocellular carcinoma and the possible association with decreased sensitivity to cisplatin. Cancer Res 56:5330-5333.
Kazmierczak B, Hennig Y, Wanschura S, Rogalla P, Bartnitzke S, Van d, V, and Bullerdiek J (1995). Description of a novel fusion transcript between HMGI-C, a gene encoding for a member of the high mobility group proteins, and the mitochondrial aldehyde dehydrogenase gene. Cancer Res 55:6038-6039.
Kazmierczak B, Wanschura S, Rommel B, Bartnitzke S, and Bullerdiek J (1996). Ten pulmonary chondroid hamartomas with chromosome 6p21 breakpoints within the HMG-I(Y) gene or its immediate surroundings. J Natl Cancer Inst 88:1234-1236.
Kazmierczak B, Dal Cin P, Wanschura S, Borrmann L, Fusco A, Van Den Berghe H, and Bullerdiek J (1998). HMGIY is the target of 6p21.3 rearrangements in various benign mesenchymal tumors. Genes Chromosomes Cancer 23:279-285.
Kazmierczak B, Dal Cin P, Meyer-Bolte K, Van Den BH, and Bullerdiek J (1999a).
HMG1 is not rearranged by 13q12 aberrations in lipomas. Genes Chromosomes Cancer 24:290-292.
Kazmierczak B, Meyer-Bolte K, Tran KH, Wockel W, Breightman I, Rosigkeit J, Bartnitzke S, and Bullerdiek J (1999b). A high frequency of tumors with rearrangements of genes of the HMGI(Y) family in a series of 191 pulmonary chondroid hamartomas. Genes Chromosomes Cancer 26:125-133.
Lanahan A, Williams JB, Sanders LK, and Nathans D (1992). Growth factor-induced delayed early response genes. Mol Cell Biol 12:3919-3929.
Landsman D and Bustin M (1993). A signature for the HMG-1 box DNA-binding proteins. Bioessays 15:539-546.
Levenson AS and Jordan VC (1997). MCF-7: the first hormone-responsive breast cancer cell line. Cancer Res 57:3071-3078.
Liu J, Schiltz JF, Shah PC, Benson KF, and Chada KK (2000). Genomic structure and expression of the murine Hmgi(y) gene. Gene 246:197-207.
Liu WM, Guerra-Vladusic FK, Kurakata S, Lupu R, and Kohwi-Shigematsu T (1999).
HMG-I(Y) recognizes base-unpairing regions of matrix attachment sequences and its increased expression is directly linked to metastatic breast cancer phenotype.
Cancer Res 59:5695-5703.
Long M and Langley CH (1993). Natural selection and the origin of jingwei, a chimeric processed functional gene in Drosophila. Science 260:91-95.
Loveday RL, Greenman J, Simcox DL, Speirs V, Drew PJ, Monson JR, and Kerin MJ (2000). Genetic changes in breast cancer detected by comparative genomic hybridisation. Int J Cancer 86:494-500.
Lykkesfeldt AE and Sorensen EK (1992). Effect of estrogen and antiestrogens on cell proliferation and synthesis of secreted proteins in the human breast cancer cell line MCF-7 and a tamoxifen resistant variant subline, AL-1. Acta Oncol 31:131-138.
Masciullo V, Baldassarre G, Pentimalli F, Berlingieri MT, Boccia A, Chiappetta G, Palazzo J, Manfioletti G, Giancotti V, Viglietto G, Scambia G, and Fusco A (2003).
HMGA1 protein over-expression is a frequent feature of epithelial ovarian carcinomas. Carcinogenesis 24:1191-1198.
Massaad-Massade L, Navarro S, Krummrei U, Reeves R, Beaune P, and Barouki R (2002). HMGA1 enhances the transcriptional activity and binding of the estrogen receptor to its responsive element. Biochemistry 41:2760-2768.
McCarrey JR and Thomas K (1987). Human testis-specific PGK gene lacks introns and possesses characteristics of a processed gene. Nature 326:501-505.
Mercola M, Wang CY, Kelly J, Brownlee C, Jackson-Grusby L, Stiles C, and Bowen-Pope D (1990). Selective expression of PDGF A and its receptor during early mouse embryogenesis. Dev Biol 138:114-122.
Meyer B, Murua Escobar H, Hauke S, Richter A, Winkler S, Rogalla P, Flohr AM, Bullerdiek J, and Nolte I (in press). Expression Pattern of the HMGB1 Gene in Sarcomas of the Dog. Anticancer Res 24.
Miller SA, Dykes, DD, and Polesky HF (1988). A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215.
Molina R, Duffy MJ, Aronsson AC, Lamerz R, Stieber P, and van Dalen H (1999).
Tumour markers in breast cancer--EGTM recommendations. European Group on Tumor Markers. Anticancer Res 19:2803-2805.
Müller S, Scaffidi P, Degryse B, Bonaldi T, Ronfani L, Agresti A, Beltrame M, and Bianchi ME (2001). New EMBO members' review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal. EMBO J 20:4337-4340.
Murua Escobar H, Meyer B, Richter A, Becker K, Flohr AM, Bullerdiek J, and Nolte I (2003). Molecular characterization of the canine HMGB1. Cytogenet Genome Res 101:33-38.
Nagatani G, Nomoto M, Takano H, Ise T, Kato K, Imamura T, Izumi H, Makishima K, and Kohno K (2001). Transcriptional activation of the human HMG1 gene in cisplatin- resistant human cancer cells. Cancer Res 61:1592-1597.
Nagourney RA, Link JS, Blitzer JB, Forsthoff C, and Evans SS (2000). Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients. J Clin Oncol 18:2245-2249.
Nam ES, Kim DH, Cho SJ, Chae SW, Kim HY, Kim SM, Han JJ, Shin HS, and Park YE (2003). Expression of HMGI(Y) associated with malignant phenotype of human gastric tissue. Histopathology 42:466-471.
Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, Elliston K, Stern D, and Shaw A (1992). Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267:14998-15004.
Ng SY, Gunning P, Eddy R, Ponte P, Leavitt J, Shows T, and Kedes L (1985).
Evolution of the functional human beta-actin gene and its multi- pseudogene family:
conservation of noncoding regions and chromosomal dispersion of pseudogenes.
Mol Cell Biol 5:2720-2732.
Nilbert M and Heim S (1990). Uterine leiomyoma cytogenetics. Genes Chromosomes Cancer 2:3-13.
Nilbert M, Jin YS, Heim S, Mandahl N, Floderus UM, Willen H, and Mitelman F (1990a). Chromosome rearrangements in two uterine sarcomas. Cancer Genet Cytogenet 44:27-35.
Nilbert M, Mandahl N, Heim S, Rydholm A, Helm G, Willen H, Baldetorp B, and Mitelman F (1990b). Complex karyotypic changes, including rearrangements of 12q13 and 14q24, in two leiomyosarcomas. Cancer Genet Cytogenet 48:217-223.
Ohndorf UM, Rould MA, He Q, Pabo CO, and Lippard SJ (1999). Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins. Nature 399:708-712.
Olert J, Wiedorn KH, Goldmann T, Kuhl H, Mehraein Y, Scherthan H, Niketeghad F, Vollmer E, Muller AM, and Muller-Navia J (2001). HOPE fixation: a novel fixing method and paraffin-embedding technique for human soft tissues. Pathol Res Pract 197:823-826.
Onate SA, Prendergast P, Wagner JP, Nissen M, Reeves R, Pettijohn DE, and Edwards DP (1994). The DNA-bending protein HMG-1 enhances progesterone receptor binding to its target DNA sequences. Mol Cell Biol 14:3376-3391.
Pauken CM, Nagle DL, Bucan M, and Lo CW (1994). Molecular cloning, expression analysis, and chromosomal localization of mouse Hmg1-containing sequences.
Mamm Genome 5:91-99.
Pegram MD and Slamon DJ (1999). Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity. Semin Oncol 26:89-95.
Pellacani A, Chin MT, Wiesel P, Ibanez M, Patel A, Yet SF, Hsieh CM, Paulauskis JD, Reeves R, Lee ME, and Perrella MA (1999). Induction of high mobility group-I(Y) protein by endotoxin and interleukin-1beta in vascular smooth muscle cells. Role in activation of inducible nitric oxide synthase. J Biol Chem 274:1525-1532.
Petit MM, Mols R, Schoenmakers EF, Mandahl N, and Van de Ven WJ (1996). LPP, the preferred fusion partner gene of HMGIC in lipomas, is a novel member of the LIM protein gene family. Genomics 36:118-129.
Pierantoni GM, Battista S, Pentimalli F, Fedele M, Visone R, Federico A, Santoro M, Viglietto G, and Fusco A (2003). A truncated HMGA1 gene induces proliferation of the 3T3-L1 pre-adipocytic cells: a model of human lipomas. Carcinogenesis 24:1861-1869.
Pil PM and Lippard SJ (1992). Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin. Science 256:234-237.
Poser I, Golob M, Buettner R, and Bosserhoff AK (2003). Upregulation of HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype. Mol Cell Biol 23:2991-2998.
Powles TJ (1997). Efficacy of tamoxifen as treatment of breast cancer. Semin Oncol 24:S1.
Rappolee DA, Brenner CA, Schultz R, Mark D, and Werb Z (1988). Developmental expression of PDGF, TGF-alpha, and TGF-beta genes in preimplantation mouse embryos. Science 241:1823-1825.
Reeck GR, Isackson PJ, and Teller DC (1982). Domain structure in high molecular weight high mobility group nonhistone chromatin proteins. Nature 300:76-78.
Reeves R (2000). Structure and function of the HMGI(Y) family of architectural transcription factors. Environ Health Perspect 108 Suppl 5:803-809.
Reeves R and Nissen MS (1990). The A.T-DNA-binding domain of mammalian high mobility group I chromosomal proteins. A novel peptide motif for recognizing DNA structure. J Biol Chem 265:8573-8582.
Reeves R and Beckerbauer L (2001). HMGI/Y proteins: flexible regulators of transcription and chromatin structure. Biochim Biophys Acta 1519:13-29.
Reeves R, Edberg DD, and Li Y (2001). Architectural transcription factor HMGI(Y) promotes tumor progression and mesenchymal transition of human epithelial cells.
Mol Cell Biol 21:575-594.
Remmele W and Stegner HE (1987). [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe 8:138-140.
Rogalla P, Drechsler K, Frey G, Hennig Y, Helmke B, Bonk U, and Bullerdiek J (1996). HMGI-C expression patterns in human tissues. Implications for the genesis of frequent mesenchymal tumors. Am J Pathol 149:775-779.
Rogalla P, Drechsler K, Kazmierczak B, Rippe V, Bonk U, and Bullerdiek J (1997).
Expression of HMGI-C, a member of the high mobility group protein family, in a subset of breast cancers: relationship to histologic grade. Mol Carcinog 19:153-156.
Rogalla P, Borda Z, Meyer-Bolte K, Tran KH, Hauke S, Nimzyk R, and Bullerdiek J (1998a). Mapping and molecular characterization of five HMG1-related DNA sequences. Cytogenet Cell Genet 83:124-129.
Rogalla P, Drechsler K, Schroder-Babo W, Eberhardt K, and Bullerdiek J (1998b).
HMGIC expression patterns in non-small lung cancer and surrounding tissue.
Anticancer Res 18:3327-3330.
Rogalla P, Kazmierczak B, Flohr AM, Hauke S, and Bullerdiek J (2000). Back to the roots of a new exon--the molecular archaeology of a SP100 splice variant. Genomics 63:117-122.
Rogalla P, Blank C, Helbig R, Wosniok W, and Bullerdiek J (2001). Significant correlation between the breakpoints of rare clonal aberrations in benign solid tumors and the assignment of HMGIY retropseudogenes. Cancer Genet Cytogenet 130:51-56.
Romine LE, Wood JR, Lamia LA, Prendergast P, Edwards DP, and Nardulli AM (1998). The high mobility group protein 1 enhances binding of the estrogen receptor DNA binding domain to the estrogen response element. Mol Endocrinol 12:664-674.
Rommel B, Rogalla P, Jox A, Kalle CV, Kazmierczak B, Wolf J, and Bullerdiek J (1997). HMGI-C, a member of the high mobility group family of proteins, is expressed in hematopoietic stem cells and in leukemic cells. Leuk Lymphoma 26:603-607.
Ross R, Raines EW, and Bowen-Pope DF (1986). The biology of platelet-derived growth factor. Cell 46:155-169.
Sachs L (1992). Angewandte Statistik, 7. Aufl., Springer-Verlag, Berlin, 309-312.
Sauer K and Lehner CF (1995). The role of cyclin E in the regulation of entry into S phase. Prog Cell Cycle Res 1:125-139.
Scala S, Portella G, Fedele M, Chiappetta G, and Fusco A (2000). Adenovirus-mediated suppression of HMGI(Y) protein synthesis as potential therapy of human malignant neoplasias. Proc Natl Acad Sci U S A 97:4256-4261.
Schlueter C, Hauke S, Flohr AM, Rogalla P, and Bullerdiek J (2003). Tissue-specific expression patterns of the RAGE receptor and its soluble forms--a result of regulated alternative splicing? Biochim Biophys Acta 1630:1-6.
Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL, and Stern D (1994). Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb 14:1521-1528.
Schoenmakers EF, Wanschura S, Mols R, Bullerdiek J, Van Den Berghe, and Van de Ven WJ (1995). Recurrent rearrangements in the high mobility group protein gene, HMGI- C, in benign mesenchymal tumours. Nat Genet 10:436-444.
Schwendel A, Richard F, Langreck H, Kaufmann O, Lage H, Winzer KJ, Petersen I, and Dietel M (1998). Chromosome alterations in breast carcinomas: frequent involvement of DNA losses including chromosomes 4q and 21q. Br J Cancer 78:806-811.
Seeler JS, Marchio A, Sitterlin D, Transy C, and Dejean A (1998). Interaction of SP100 with HP1 proteins: a link between the promyelocytic leukemia-associated nuclear bodies and the chromatin compartment. Proc Natl Acad Sci U S A 95:7316-7321.
Seeler JS, Marchio A, Losson R, Desterro JM, Hay RT, Chambon P, and Dejean A (2001). Common properties of nuclear body protein SP100 and TIF1alpha chromatin factor: role of SUMO modification. Mol Cell Biol 21:3314-3324.
Sen GR, Hillemann D, Kubica T, Zissel G, Muller-Quernheim J, Galle J, Vollmer E, and Goldmann T (2003). HOPE-fixation enables improved PCR-based detection and differentiation of Mycobacterium tuberculosis complex in paraffin-embedded tissues.
Pathol Res Pract 199:619-623.
Seymour L, Dajee D, and Bezwoda WR (1993). Tissue platelet derived-growth factor (PDGF) predicts for shortened survival and treatment failure in advanced breast cancer. Breast Cancer Res Treat 26:247-252.
Seymour L and Bezwoda WR (1994). Positive immunostaining for platelet derived growth factor (PDGF) is an adverse prognostic factor in patients with advanced breast cancer. Breast Cancer Res Treat 32:229-233.
Shuey DJ, McCallus DE, and Giordano T (2002). RNAi: gene-silencing in therapeutic intervention. Drug Discov Today 7:1040-1046.
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, and McGuire WL (1987).
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182.
Sornberger KS, Weremowicz S, Williams AJ, Quade BJ, Ligon AH, Pedeutour F, Vanni R, and Morton CC (1999). Expression of HMGIY in three uterine leiomyomata with complex rearrangements of chromosome 6. Cancer Genet Cytogenet 114:9-16.
Strichman-Almashanu LZ, Bustin M, and Landsman D (2003). Retroposed copies of the HMG genes: a window to genome dynamics. Genome Res 13:800-812.